Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 11
Submit an article Journal homepage
71
Views
7
CrossRef citations to date
0
Altmetric
Review

Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia

Edward D Huey National Institute of Neurological Disorders and Stroke, National Institutes of Health, Cognitive Neuroscience Section, Building 10, Room 7D43, MSC 1440, Bethesda, MD 20892-1440, USA +1 301 402 2584; +1 301 480 2909; [email protected]; Litwin-Zucker Center for Research on Alzheimer's disease, North Shore/Long Island Jewish Healthcare System, 350 Community Drive, Manhasset, NY 11030-3816, USA
, MD,
Nicole Armstrong National Institute of Neurological Disorders and Stroke, National Institutes of Health, Cognitive Neuroscience Section, Building 10, Room 7D43, MSC 1440, Bethesda, MD 20892-1440, USA +1 301 402 2584; +1 301 480 2909; [email protected]; Litwin-Zucker Center for Research on Alzheimer's disease, North Shore/Long Island Jewish Healthcare System, 350 Community Drive, Manhasset, NY 11030-3816, USA
, BS,
Parastoo Momeni Texas Tech University Health Sciences Center, Department of Neurology, Lubbock, TX 79430, USA.
, PhD &
Jordan Grafman National Institute of Neurological Disorders and Stroke, National Institutes of Health, Cognitive Neuroscience Section, Building 10, Room 7D43, MSC 1440, Bethesda, MD 20892-1440, USA +1 301 402 2584; +1 301 480 2909; [email protected]
, PhD
Pages 1367-1376 | Published online: 14 Oct 2008

Bibliography

  • Lund/Manchester. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994;57:416-8
  • Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54
  • McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-9
  • Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006;129:3051-65
  • Knibb JA, Hodges JR. Semantic dementia and primary progressive aphasia: a problem of categorization? Alzheimer Dis Assoc Disord 2005;(19 Suppl 1):S7-14
  • Mesulam MM. Primary progressive aphasia–a language-based dementia. N Engl J Med 2003;349:1535-42
  • Libon DJ, Xie SX, Moore P, et al. Patterns of neuropsychological impairment in frontotemporal dementia. Neurology 2007;68:369-75
  • Elderkin-Thompson V, Boone KB, Hwang S, Kumar A. Neurocognitive profiles in elderly patients with frontotemporal degeneration or major depressive disorder. J Int Neuropsychol Soc 2004;10:753-71
  • Wittenberg D, Possin KL, Rascovsky K, et al. The early neuropsychological and behavioral characteristics of frontotemporal dementia. Neuropsychol Rev 2008;18:91-102
  • Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol 2005;4:771-80
  • Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003;126:2016-22
  • Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002;58:1615-21
  • Bird T, Knopman D, VanSwieten J, et al. Epidemiology and genetics of frontotemporal dementia/Pick's disease. Ann Neurol 2003;54:S29-31
  • The Clinical Diagnosis and Imaging/Biomarkers Group Summary and Suggestions for Future Resource Development and Research Initiatives Frontotemporal Dementia Workshop. Available from: http://www.ninds.nih.gov/news_and_events/proceedings/Frontotemporal_Dementia_Workshop.htm [Last accessed September 24 2008]
  • Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55:335-46
  • Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008;65:249-55
  • Zahn R, Moll J, Krueger F, et al. Social concepts are represented in the superior anterior temporal cortex. Proc Natl Acad Sci USA 2007;104:6430-5
  • Seeley WW, Bauer AM, Miller BL, et al. The natural history of temporal variant frontotemporal dementia. Neurology 2005;64:1384-90
  • Rosso SM, Roks G, Stevens M, et al. Complex compulsive behaviour in the temporal variant of frontotemporal dementia. J Neurol 2001;248:965-70
  • Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol 2007;6:1004-14
  • Pick A. Uber die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Medizinische Wochenschrift 1892;17:165-7
  • Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007;114:5-22
  • Mackenzie JR, Shi J, Shaw CL, et al. Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 2006;112(5):551-9
  • Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3
  • Mackenzie IR, Foti D, Woulfe J, Hurwitz TA. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 2008;131:1282-93
  • Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59:1077-79
  • Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56:399-406
  • Alzheimer A. Uber eigenartige Krankheitsfalle des spate en Alters. Zeitschrift fur die Gesamte Neurologie und Psychiatrie.1911;4:356-85
  • Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics 2007;8(4):237-48
  • Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006;129:1385-98
  • The Pathology Working Group Summary and Suggestions for Future Resource Development and Research Initiatives Frontotemporal Dementia Workshop. Available from: http://www.ninds.nih.gov/news_and_events/proceedings/Frontotemporal_Dementia_Workshop.htm [Last accessed September 24 2008]
  • Knopman DS, Boeve BS, Caselli RJ, et al. Longitudinal tracking of FTLD: toward developing clinical trial methodology. Alzheimer Dis Assoc Disord 2007;21:S58-63
  • Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006;66:17-22
  • Freedman M. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sci 2007;34:S118-24
  • Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2007;21(4):S64-69
  • Chow TW. Treatment approaches to symptoms associated with frontotemporal degeneration. Curr Psychiatry Rep 2005;7(5):376-80
  • Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
  • Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology 2005;65:S7-19
  • Kertesz A, McMonagle P, Blair M, et al. The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996-2005
  • Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003;9:275-308
  • Diehl-Schmid J, Forstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 2008;23(7):754-9
  • Available from: www.clinicaltrials.gov/ ct2/show/NCT00545974?term= frontotemporal+dementia&rank=. [Last accessed September 24 2008]
  • Available from: www.clinicaltrials.gov/ ct2/show/NCT00200538?term= frontotemporal+dementia&rank=11. [Last accessed September 24 2008]
  • Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008;25:178-85
  • Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998;8:321-45
  • Tan HY, Chen Q, Goldberg TE, et al. Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory. J Neurosci 2007;27:13393-401
  • Available from: www.clinicaltrials.gov/ ct2/show/NCT00127114?term= frontotemporal+dementia&rank=10. [Last accessed September 24 2008]
  • Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998;95:9991-6
  • Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002;15:246-56
  • Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2006;32:1011-20
  • Available from: www.clinicaltrials.gov/ ct2/show/NCT00604591?term= frontotemporal+dementia&rank=9. [Last accessed September 24 2008]
  • Coppola G, Karydas A, Rademakers R, et al. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 2008;64(1):92-6
  • Foulds P, McAuley E, Gibbons L, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol 2008;116(2):141-6
  • Hardy J, Momeni P, Traynor BJ. Frontal temporal dementia: dissecting the aetiology and pathogenesis. Brain 2006;129:830-1
  • Huey ED, Grafman J, Wassermann EM, et al. Characteristics of frontotemporal dementia patients with a progranulin mutation. Ann Neurol 2006;60:374-80
  • Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37:806-8
  • Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36:377-81
  • Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006;129:868-76
  • Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006;66:839-44
  • Momeni P, Schymick J, Jain S, et al. Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol 2006;6:44
  • Blair IP, Bennett CL, Abel A, et al. A gene for autosomal dominant juvenile amyotrophic lateral sclerosis (ALS4) localizes to a 500-kb interval on chromosome 9q34. Neurogenetics 2000;3(1):1-6
  • Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000;284(13):1664-9
  • Ostojic J, Axelman K, Lannfelt L, Froelich-Fabre S. No evidence of linkage to chromosome 9q21-22 in a Swedish family with frontotemporal dementia and amyotrophic lateral sclerosis. Neurosci Lett 2003;340(3):245-7
  • Poorkaj P, Grossman M, Steinbart E, et al. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 2001;58:383-7
  • Rosso SM, Kamphorst W, de Graaf B, et al. Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. Brain 2001;124:1948-57
  • Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-9
  • Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry 1992;31:10626-33
  • Available from: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=1&ML= 1&Page=MutByQuery&Query=tblContexts.GeneSymbol%20In%20(‘MAPT’)& Selection=Gene%20In%20(MAPT)& CFID=136313&CFTOKEN=48500543
  • Brandt R, Hundelt M, Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta 2005;1739:331-54
  • Delacourte A, Robitaille Y, Sergeant N, et al. Specific pathological Tau protein variants characterize Pick's disease. J Neuropathol Exp Neurol 1996;55:159-68
  • Buee Scherrer V, Hof PR, Buee L, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol 1996;91:351-9
  • Wada H, Nakajoh K, Satoh-Nakagawa T, et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001;47:271-6
  • Togo T, Sahara N, Yen SH, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002;61:547-56
  • Malkani R, D'Souza I, Gwinn-Hardy K, et al. MAPT mutation in a regulatory element upstream of exon 10 causes frontotemporal dementia. Neurobiol Dis 2006;22:401-3
  • Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5
  • Spillantini MG, Murrell JR, Goedert M, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998;95:7737-41
  • Momeni P, Pittman A, Lashley T, et al. Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation. Neurobiol Aging: Published online 27 August 2007. doi:10.1016/j.neurobiolaging.2007.07.013
  • Dawson HN, Cantillana V, Chen L, Vitek MP. The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J Neurosci 2007;27(34):9155-68
  • Hutton M. “Missing” tau mutation identified. Ann Neurol 2000;47:417-8
  • Buguiani O,Murrell JR,Giaccone G, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999;58:667-77
  • Hasegawa M, Smith MJ,Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 1998;437:207-10
  • Goedert M, Jakes R, Crowther RA. Effects of frontotemporal dementia FTDP-17 mutations on heparin- induced assembly of tau filaments. FEBS Lett 1999;450:306-11
  • Rademakers R, Baker M, Gass J, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative. Lancet Neurol 2007;6(10):857-68
  • Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration. J Neurochem 2008;104:287-97
  • Daniel R, He Z, Carmichael KP, et al. Cellular localization of gene expression for progranulin. J Histochem Cytochem 2000;48:999-1009
  • Bateman A, Belcourt D, Bennett H, et al. Granulins, a novel class of peptide from leukocytes. Biochem Biophys Res Commun 1990;173:1161-8
  • He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003;81:600-12
  • Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002;111:867-78
  • Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging, and genetic study. Brain 2008;131:732-46
  • Pickering-Brown SM, Rollinson S, Du Plessis D, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 2008;131:721-31
  • Beck J, Rohrer JD, Campbell T, et al. A distinct clinical, neuropsychological, and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 2008;131:706-20
  • Anderton BH, Betts J, Blackstock WP, et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp 2001;73-80
  • The Therapeutics Working Group Summary and Suggestions for Future Resource Development and Research Initiatives Frontotemporal Dementia Workshop. Available from: www.ninds.nih.gov/news_and_events/proceedings/Frontotemporal_Dementia_Workshop.htm 2007
  • Gotschel F, Kern C, Lang S, et al. Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis. Exp Cell Res 2008;314:1351-66
  • Gomez-Ramos A, Dominguez J, Zafra D, et al. Inhibition of GSK3 dependent tau phosphorylation by metals. Curr Alzheimer Res 2006;3:123-7
  • Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 2005;118:89-99
  • Engel T, Goni-Oliver P, Gomez de Barreda E, et al. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis 2008;5:247-9
  • Engel T, Goni-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006;99:1445-55
  • Le Corre S, Klafki HW, Plesnila N, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 2006;103:9673-8
  • Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-7
  • Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41:789-813
  • Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411-9
  • Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994;34:280-5
  • Haddjeri N, Szabo ST, de Montigny C, Blier P. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology 2000;22:346-56
  • Massot O, Rousselle JC, Fillion MP, et al. 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders. Neuropsychopharmacology 1999;21:530-41
  • Macdonald A, Briggs K, Poppe M, et al. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008;23:704-11
  • Mur M, Portella MJ, Martinez-Aran A, et al. Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. J Clin Psychiatry 2007;68:1078-86
  • Senturk V, Goker C, Bilgic A, et al. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord 2007;9(Suppl 1):136-44
  • Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004
  • Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007;4(7):1-13
  • Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337-51
  • The Genetics Working Group Summary and Suggestions for Future Resource Development and Research Initiatives Frontotemporal Dementia Workshop. Available from: www.ninds.nih.gov/news_and_events/proceedings/Frontotemporal_Dementia_Workshop.htm 2007. [Last accessed September 24 2008]
  • Rankin KP, Santos-Modesitt W, Kramer JH, et al. Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. J Clin Psychiatry 2008;69:60-73
  • Diagnostic and statistical manual of mental disorders DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000
  • Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord 2007;21:S79-87

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.